Immuron Receives TGA GMP Clearance Highlights: Immuron Receives TGA GMP Clearance Immuron to release and dispatch Travelan to customers this week Melbourne, Australia

Immuron Receives TGA GMP Clearance

Melbourne, Australia, August 9, 2023: Immuron

Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that

the Therapeutic Goods Administration (TGA) has given GMP Clearance for Immuron's packaging supplier allowing Travelan to be

released for sale in Australia to retail pharmacy wholesalers and other customers.

On July 5, 2023, Immuron announced FY23 sales increase of 136% on FY22

sales and at the same time advised that until the TGA provided GMP Clearance for a new packaging supplier, Travelan would be out

of stock in wholesalers and pharmacies. If Immuron was able to supply product to wholesalers in June, FY23 sales would have been even

higher. Immuron plans to release and dispatch Travelan to customers this week.

Immuron's resolution of supply and stock outages will allow continuation

of anticipated growth in sales in Australia and also USA where Immuron recently launched on its own Amazon.com shopfront.

Immuron is focused on growing sales of its commercial

products, expanding its portfolio of products and has a strong existing pipeline.

This release has been authorised by the directors

orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a

digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly

purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing

bacteria and prevent colonization and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed

medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea,

reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product

(NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement

for digestive tract protection.

About Travelers' diarrhea

is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,

and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant

causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella

spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused

with travelers' diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.

Immuron Limited (ASX:

IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal

antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information

visit: http://www.immuron.com

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking

statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,

each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development

programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations

and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock

value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth

strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the

results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties

relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key

personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and

intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation

or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in

our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.